NCT06621472 Retrolaminar Block Versus Subcostal Transversus Abdominis Plane Block in Liver Resection Surgery
| NCT ID | NCT06621472 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Cancer Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-10-01 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Adequate pain control improves postoperative outcomes and is imperative for enhanced recovery after surgery (ERAS) . Open liver resection surgery is associated with intraoperative blood loss, hypotension, coagulopathy, pulmonary complications, liver impairment, and renal impairment, making perioperative pain management challenging . Multimodal analgesic strategies employing regional techniques decrease postoperative pain and opioid consumption following liver resections. Thoracic epidural analgesia (TEA) is considered the 'gold standard' for open thoracic and abdominal surgical procedures .
Eligibility Criteria
Inclusion Criteria: Physical status American Society of Anesthesiologists (ASA)II, III. Body mass index (BMI): 20-35 kg/m2. Exclusion Criteria: Patient refusal Physical status ASA IV BMI \< 20 kg/m2 and \>35 kg/m2 known sensitivity or contraindication to drug used in the study (local anesthetics, opioids). History of psychological disorders and/or chronic pain. Contraindication to regional anesthesia e.g., local sepsis, pre- existing peripheral neuropathies, and coagulopathy. Severe respiratory, cardiac disorders and renal disease.
Contact & Investigator
sayed M Abed
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06621472 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Cancer Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06621472 currently recruiting?
Yes, NCT06621472 is actively recruiting participants. Contact the research team at sydabed2020@outlook.com for enrollment information.
Where is the NCT06621472 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06621472 clinical trial?
NCT06621472 is sponsored by Cairo University. The principal investigator is sayed M Abed at Cairo University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.